Sun Pharmaceutical Industries Limited (BOM:524715)
India · Delayed Price · Currency is INR | Market Cap | 3.97T |
| Revenue (ttm) | 537.77B |
| Net Income (ttm) | 103.72B |
| Shares Out | n/a |
| EPS (ttm) | 43.25 |
| PE Ratio | 38.31 |
| Forward PE | 32.65 |
| Dividend | 16.00 (0.99%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 229,233 |
| Average Volume | 128,734 |
| Open | 1,651.40 |
| Previous Close | 1,648.90 |
| Day's Range | 1,642.20 - 1,668.40 |
| 52-Week Range | 1,555.00 - 1,960.20 |
| Beta | n/a |
| RSI | 60.90 |
| Earnings Date | Oct 31, 2025 |
About BOM:524715
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respira... [Read more]
Financial Performance
In 2024, BOM:524715's revenue was 525.78 billion, an increase of 8.42% compared to the previous year's 484.97 billion. Earnings were 109.29 billion, an increase of 14.12%.
Financial StatementsNews
Nifty top gainers today, September 18: Eternal, HDFC Life, Sun Pharma, Cipla, Infosys and more
Indian equity benchmarks closed higher on September 18. The BSE Sensex rose 320.25 points, or 0.39%, to end at 83,013.96, while the NSE Nifty 50 gained 93.35 points, or 0.37%, to finish at 25,423.60. ...
ICICI Bank, PNB Housing, Sun Pharma, D-Mart, Shriram Finance among top picks with 15–35% upside, say brokerages
Brokerage notes released today pointed out several stocks that could deliver more than 15% potential upside from current levels. The key highlights are presented in the table below: Stock Brokerage Ca...
Sun Pharma share: Citi maintains buy, sees 35% upside on innovation revenue growth and global expansion
Sun Pharma stock: Citi target at ₹2,180 implies 34.6% gain, driven by Ilumya approval and US expansion
Top stocks to watch today, September 10: Bajaj Auto, Eicher Motors, Yes Bank, Sun Pharma and more
Indian equities are expected to see stock-specific action today as several companies announced key developments and updates. Here are the major stocks to watch on Tuesday, September 10: Bajaj Auto: Th...
Sun Pharma Halol facility classified as “Official Action Indicated” by US FDA
Sun Pharmaceutical Industries Ltd. informed exchanges that the US Food and Drug Administration (FDA) has classified its Halol facility as “Official Action Indicated (OAI)” following an inspection cond...
Nifty 50 top losers this month, August 2025: Adani Enterprises, Shriram Finance, IndusInd Bank, Sun Pharma and more
Indian equity markets ended August 29 on a weak note, with the Sensex closing 270.92 points lower at 79,809.65 and the Nifty slipping 74.05 points to 24,426.85. As per Trendline data, here are the top...
Sun Pharma share slips 2% as BofA Securities downgrades to underperform, cuts target
Shares of Sun Pharmaceutical Industries came under pressure on Tuesday after BofA Securities downgraded the stock to “Underperform” from its earlier positive stance, while also cutting the target pric...
Top stocks to buy today: Recommendations for August 26- check list
Stock market recommendations: Mirae Asset Sharekhan's Somil Mehta recommends buying Sun Pharma and Bharti Airtel. Sun Pharma, exhibiting a breakout from a triangle pattern, is projected to rise, targe...
Nifty 50 top losers today, August 6: Wipro, Sun Pharma, Jio Financial Services, Tech Mahindra and more
Indian stock markets continued their downward momentum for a second straight day on August 6, with benchmark indices closing in the red amid weak investor sentiment. The Nifty 50 slipped below the psy...
Raymond to Dr Reddy's: Textiles, pharma stocks bear tariffs brunt
Following US President Trump's tariff announcement, Indian pharmaceutical and textile companies experienced significant stock declines. Gokaldas Exports saw the steepest fall at 15.9%, with other text...
Nifty 50 top losers today, August 1: Sun Pharma, Dr. Reddy’s Laboratories, Adani Enterprises, Cipla and more
Indian equity markets ended Friday’s session (August 1) on a weak note, with both benchmark indices registering sharp declines. The BSE Sensex fell 585.67 points to settle at 80,599.91, while the NSE ...
Sun Pharma share: Morgan Stanley and HSBC stay positive, see upside up to Rs 1,948 on steady growth and strong India business
Sun Pharmaceutical Industries has received optimistic commentary from both Morgan Stanley and HSBC following its recent updates, with both brokerages maintaining positive ratings and expecting further...
Stocks to watch on brokerages, August 1: JSW Energy, Swiggy, TVS, Dabur, Eicher Motors, Maruti Suzuki, and Chola Finance on radar today
A flurry of brokerage activity has put several high-profile stocks in focus on Thursday, August 1. Among the names seeing active analyst commentary are JSW Energy, Dabur, Sun Pharma, Swiggy, IIFL Fina...
Nifty 50 top losers today, July 31: Adani Enterprises, Tata Steel, Sun Pharmaceutical, Dr. Reddy and more
Indian stock markets closed in the red for the second consecutive session on July 31, with the Nifty 50 slipping below the 24,800 mark. The BSE Sensex declined 296.28 points to end at 81,185.58, while...
Sun Pharma Q1 Results: Revenue rises 9.5% YoY to Rs 13,851.4 crore, net profit drops 19.6% YoY
Sun Pharmaceutical Industries Ltd. announced its financial results for the quarter ended June 30, 2025 (Q1 FY26). The company reported a steady rise in revenue but saw a notable decline in net profit ...
Nifty top gainers today, July 30: L&T, Sun Pharma, Tata Consumer Products, NTPC, Maruti Suzuki India and more
Indian stock markets wrapped up the session on a positive note on July 30, with the Nifty 50 closing at 24,855.05, marking a modest gain of 0.14%. The Sensex too edged higher by 143.91 points to finis...
Sun Pharma subsidiaries settle US antitrust litigation for $200 million
Sun Pharmaceutical Industries Limited (“Sun Pharma”) has announced that its subsidiaries, Sun Pharmaceutical Industries, Inc. (“SPII”) and Taro Pharmaceuticals U.S.A., Inc. (“Taro”), have entered into...
Sun Pharma reports positive results from Phase 3 trials for ILUMYA
Sun Pharmaceutical Industries has shared encouraging top-line results from two (Phase 3) clinical trials evaluating its biologic drug tildrakizumab 100 mg, marketed as ILUMYA®, for the treatment of ac...
Tata Technologies, Sun Pharma & more: Top stocks on brokers' radar for July 17, 2025
Brokerage firms have varying outlooks on several companies. JP Morgan downgraded Tata Technologies due to mixed Q1 results, while Goldman Sachs is optimistic about Ola Electric's path to profitability...
Nifty 50 top losers today, July 16: Shriram Finance, Eternal, Sun Pharma, Cipla, Tata Steel and more
Indian stock markets wrapped up July 16 on a quiet but positive note, with both Sensex and Nifty 50 posting modest gains. The Sensex inched up by 63.57 points to end at 82,634.48, while the Nifty 50 a...
Nifty top gainers today, July 15: Hero MotoCorp, Bajaj Auto, Sun Pharma, Shriram Finance, Apollo Hospitals and more
Indian stock markets wrapped up the day on a positive note this Monday, July 15, with both benchmark indices showing solid strength. The BSE Sensex jumped 317 points to close at 82,570.91, while the N...
Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients MUMBAI, India and PRINCETON, N.J. , July 14, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries ...
Sun Pharma announces settlement with Incyte Corporation over LEQSELVI litigation
Sun Pharmaceutical Industries Ltd announced on July 14 that it has reached a settlement and license agreement with Incyte Corporation in connection with litigation over the drug LEQSELVI™ (deuruxoliti...
Morgan Stanley turns selective on Indian pharma, initiates call on Sun Pharma, Lupin, DRL, CIPLA shares
Morgan Stanley has initiated coverage on India’s four largest pharmaceutical companies by market capitalization — Sun Pharma, Lupin, Dr. Reddy’s Labs (DRL), and Cipla — with a broadly cautious outlook...
Nomura says IPM growth accelerated to 8% in June; IPCA, Sun Pharma lead gains
Nomura has reported that India’s pharmaceutical market (IPM) grew 8% year-on-year in June 2025, driven by a recovery in acute therapies. The growth is the highest recorded in the past five months and ...